Correlation Between BioAffinity Technologies and Puma Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both BioAffinity Technologies and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BioAffinity Technologies and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between bioAffinity Technologies Warrant and Puma Biotechnology, you can compare the effects of market volatilities on BioAffinity Technologies and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BioAffinity Technologies with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of BioAffinity Technologies and Puma Biotechnology.

Diversification Opportunities for BioAffinity Technologies and Puma Biotechnology

0.02
  Correlation Coefficient

Significant diversification

The 3 months correlation between BioAffinity and Puma is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding bioAffinity Technologies Warra and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and BioAffinity Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on bioAffinity Technologies Warrant are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of BioAffinity Technologies i.e., BioAffinity Technologies and Puma Biotechnology go up and down completely randomly.

Pair Corralation between BioAffinity Technologies and Puma Biotechnology

Assuming the 90 days horizon bioAffinity Technologies Warrant is expected to generate 4.06 times more return on investment than Puma Biotechnology. However, BioAffinity Technologies is 4.06 times more volatile than Puma Biotechnology. It trades about 0.03 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.04 per unit of risk. If you would invest  53.00  in bioAffinity Technologies Warrant on December 4, 2024 and sell it today you would lose (18.00) from holding bioAffinity Technologies Warrant or give up 33.96% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy79.66%
ValuesDaily Returns

bioAffinity Technologies Warra  vs.  Puma Biotechnology

 Performance 
       Timeline  
BioAffinity Technologies 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in bioAffinity Technologies Warrant are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile technical and fundamental indicators, BioAffinity Technologies showed solid returns over the last few months and may actually be approaching a breakup point.
Puma Biotechnology 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.

BioAffinity Technologies and Puma Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with BioAffinity Technologies and Puma Biotechnology

The main advantage of trading using opposite BioAffinity Technologies and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BioAffinity Technologies position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.
The idea behind bioAffinity Technologies Warrant and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance